vTv Therapeutics Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über vTv Therapeutics Inc Unternehmen

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Azeliragon and HPP3033.

vTv Therapeutics Inc Informationen



BörsenkürzelVTVT

Name des UnternehmensvTv Therapeutics Inc

IPO-datumJul 30, 2015

CEOMr. Paul Jai Sekhri

Anzahl der mitarbeiter23

WertpapierartOrdinary Share

GeschäftsjahresendeJul 30

Addresse3980 Premier Dr

StadtHIGH POINT

BörseNASDAQ Capital Market Consolidated

LandUnited States of America

Postleitzahl27265

Telefon13368410300

Websitehttps://vtvtherapeutics.com/

BörsenkürzelVTVT

IPO-datumJul 30, 2015

CEOMr. Paul Jai Sekhri

Führungskräfte von vTv Therapeutics Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Paul Jai Sekhri

Chairman of the Board, President, Chief Executive Officer

5.00K

-82.80%

Dr. Anne M. Phillips, M.D.

Independent Director

2.15K

--

Dr. Raymond Cheong, M.D., Ph.D.

Independent Director

1.83K

--

Mr. Richard S. (Rich) Nelson

Executive Vice President - Corporate Development, Director

--

Dr. Srinivas Akkaraju, M.D., Ph.D.

Independent Director

--

-100.00%

Mr. Fahed Al Marzooqi, M.D.

Independent Director

--

Mr. Burns Mcclellan

Investor Relations

--

Dr. Michael Tung, M.D.

Executive Vice President, Chief Financial Officer

--

Mr. Daniel (Dan) Spiegelman

Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Paul Jai Sekhri

Chairman of the Board, President, Chief Executive Officer

5.00K

-82.80%

Dr. Anne M. Phillips, M.D.

Independent Director

2.15K

--

Dr. Raymond Cheong, M.D., Ph.D.

Independent Director

1.83K

--

Mr. Richard S. (Rich) Nelson

Executive Vice President - Corporate Development, Director

--

Dr. Srinivas Akkaraju, M.D., Ph.D.

Independent Director

--

-100.00%

Mr. Fahed Al Marzooqi, M.D.

Independent Director

--

Umsatzaufteilung

FY2023

Keine Daten

Nach RegionUSD

Name

Umsatz

Anteil

United States

0.00

0.00%

Nach Geschäftsbereich

Nach Region

Keine Daten

Aktionärsstatistik

Aktualisiert: Sat, Sep 13

Aktionäre

Aktionärstypen

Aktionäre

Anteil

MacAndrews & Forbes Holdings, Inc.

34.88%

Samsara BioCapital, LLC

11.95%

Trails Edge Capital Partners LP

8.83%

Fidelity Management & Research Company LLC

6.81%

Invus Public Equities LP

6.23%

Andere

31.30%

Aktionäre

Anteil

MacAndrews & Forbes Holdings, Inc.

34.88%

Samsara BioCapital, LLC

11.95%

Trails Edge Capital Partners LP

8.83%

Fidelity Management & Research Company LLC

6.81%

Invus Public Equities LP

6.23%

Andere

31.30%

Aktionärstypen

Aktionäre

Anteil

Holding Company

34.88%

Investment Advisor

24.03%

Venture Capital

11.95%

Hedge Fund

6.61%

Investment Advisor/Hedge Fund

1.09%

Individual Investor

0.63%

Andere

20.81%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

47

1.14M

43.69%

+560.06K

2025Q2

54

1.51M

57.66%

-17.51K

2025Q1

53

1.53M

60.03%

+1.63K

2024Q4

55

1.51M

61.92%

-7.51K

2024Q3

55

1.49M

61.31%

+181.69K

2024Q2

53

1.29M

53.13%

+308.00

2024Q1

64

1.68M

72.07%

+129.32K

2023Q4

64

1.40M

68.78%

-52.49K

2023Q3

72

1.41M

69.35%

-49.61K

2023Q2

81

1.40M

81.32%

+323.67K

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

MacAndrews & Forbes Holdings, Inc.

912.98K

34.88%

--

Apr 01, 2025

Samsara BioCapital, LLC

312.78K

11.95%

+106.00K

+51.26%

Sep 22, 2025

Trails Edge Capital Partners LP

231.00K

8.83%

+231.00K

--

Aug 29, 2025

Fidelity Management & Research Company LLC

178.20K

6.81%

--

Jun 30, 2025

Invus Public Equities LP

163.00K

6.23%

+163.00K

--

Aug 29, 2025

Baker Bros. Advisors LP

148.31K

5.67%

+51.00K

+52.41%

Sep 03, 2025

The Vanguard Group, Inc.

43.17K

1.65%

+1.62K

+3.89%

Jun 30, 2025

Northern Trust Investments, Inc.

15.29K

0.58%

-339.00

-2.17%

Jun 30, 2025

Millennium Management LLC

15.04K

0.57%

+15.04K

--

Jun 30, 2025

Geode Capital Management, L.L.C.

12.87K

0.49%

+229.00

+1.81%

Jun 30, 2025

Verbundene ETFs



Aktualisiert: 2 hours ago

Name

Anteil

iShares Micro-Cap ETF

0.01%

iShares Core S&P Total U.S. Stock Market ETF

0%

iShares Micro-Cap ETF

Anteil0.01%

iShares Core S&P Total U.S. Stock Market ETF

Anteil0%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Datum

Art

Verhältnis

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1